Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polyanalgesic titration for severe refractory pain.

BMJ supportive & palliative care·2026
Same author

Subcutaneous antibiotics in palliative medicine: Retrospective chart review.

BMJ supportive & palliative care·2025
Same author

Just-in-case drugs in the dying: home deaths retrospective chart review.

BMJ supportive & palliative care·2025
Same author

HCN channels: novel therapeutic targets for peripheral neuropathic pain.

BMJ supportive & palliative care·2025
Same author

Lacosamide in palliative medicine: a retrospective chart review.

BMJ supportive & palliative care·2024
Same author

Transdermal clonidine for agitation and pain.

BMJ supportive & palliative care·2024

Related Experiment Video

Updated: Jun 26, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.0K

Beta-blockers for tenacious saliva: a case report.

Myles J Woodman1, Paul Howard2,3

  • 1Department of General Medicine, St Mary's Hospital, Isle of Wight NHS Trust, Newport, Isle of Wight, UK.

BMJ Supportive & Palliative Care
|March 25, 2022
PubMed
Summary

This case report highlights a potential new treatment for thick, tenacious oropharyngeal secretions in head and neck cancer patients. Oral atenolol showed subjective benefit, suggesting beta-blockers may help manage these challenging symptoms.

Keywords:
Drug administrationHead and neckNeurological conditions

More Related Videos

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

23.5K
Murine Salivary Functional Assessment via Pilocarpine Stimulation Following Fractionated Radiation
09:10

Murine Salivary Functional Assessment via Pilocarpine Stimulation Following Fractionated Radiation

Published on: May 4, 2018

11.5K

Related Experiment Videos

Last Updated: Jun 26, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.0K
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

23.5K
Murine Salivary Functional Assessment via Pilocarpine Stimulation Following Fractionated Radiation
09:10

Murine Salivary Functional Assessment via Pilocarpine Stimulation Following Fractionated Radiation

Published on: May 4, 2018

11.5K

Area of Science:

  • Oncology
  • Pharmacology
  • Otorhinolaryngology

Background:

  • Metastatic head and neck cancer can cause intractable oropharyngeal secretions, significantly impacting patient quality of life.
  • Current management strategies for tenacious secretions are often limited, necessitating exploration of novel therapeutic approaches.

Approach:

  • This case report details the management of a 75-year-old male patient with metastatic head and neck cancer experiencing severe oropharyngeal secretions.
  • The patient received oral atenolol, a beta-blocker, for symptomatic relief.

Key Points:

  • The patient reported subjective improvement in secretion viscosity and tenacity with oral atenolol.
  • A literature review found no prior studies on beta-blocker use for secretions in malignant disease, but noted anecdotal use in motor neuron disease.
  • A proposed mechanism involves beta-1 blockade reducing salivary protein content and viscosity.

Conclusions:

  • Beta-blockers, specifically atenolol, may offer a novel therapeutic option for managing symptomatic tenacious oropharyngeal secretions in advanced cancer.
  • Further research is warranted to investigate the role of beta-adrenoreceptors in secretion viscosity and the efficacy of beta-blockers in this context.